ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
BeiGene Ltd

BeiGene Ltd (BGNE)

156.39
1.31
(0.84%)
Closed March 29 04:00PM
156.35
-0.04
(-0.03%)
After Hours: 07:59PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
156.39
Bid
150.53
Ask
160.00
Volume
104,129
155.09 Day's Range 157.38
0.00 52 Week Range 0.00
Market Cap
Previous Close
155.08
Open
157.00
Last Trade
1
@
155.51
Last Trade Time
Financial Volume
$ 16,295,798
VWAP
156.4963
Average Volume (3m)
-
Shares Outstanding
1,359,498,000
Dividend Yield
-
PE Ratio
-22.03
Earnings Per Share (EPS)
-0.65
Revenue
2.46B
Net Profit
-881.71M

About BeiGene Ltd

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system ... BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Grand Cayman, Cym
Founded
1970
BeiGene Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BGNE. The last closing price for BeiGene was $155.08. Over the last year, BeiGene shares have traded in a share price range of $ 0.00 to $ 0.00.

BeiGene currently has 1,359,498,000 shares outstanding. The market capitalization of BeiGene is $19.43 billion. BeiGene has a price to earnings ratio (PE ratio) of -22.03.

BGNE Latest News

BeiGene、化学療法後の進行性または転移性食道扁平上皮癌の治療のためのTEVIMBRA®のFDA承認取得

グローバルに実施した、3相RATIONALE 302治験は、TEVIMBRAが以前に全身治療を受けた患者において、化学療法と比較して長い生存期間を示した 承認は、米国におけるTEVIMBRAの最初の適応となる (ビジネスワイヤ...

百濟神州喜獲FDA批准,TEVIMBRA®將用於晚期或轉移性食管鱗狀細胞癌在化療後的治療

全球性三期RATIONALE 302臨床試驗表明,TEVIMBRA與化療相比可延長既往接受全身治療患者的生存期 本次獲批屬TEVIMBRA在美國的首個適應症 (美國商業資訊)-- 全球性腫瘤學企業百濟神州(納斯達克股票代碼:BGNE;...

BeiGene reçoit l'approbation de la FDA pour TEVIMBRA® dans le traitement du carcinome épidermoïde de l’œsophage avancé ou métastatique après une chimiothérapie

Les résultats de l’essai mondial RATIONALE 302 de Phase 3 ont montré que TEVIMBRA a prolongé la survie des patients ayant déjà reçu un traitement systémique par rapport à la chimiothérapie...

BeiGene erhält FDA-Zulassung für TEVIMBRA ® zur Behandlung des fortgeschrittenen oder metastasierten Plattenepithelkarzinoms der Speiseröhre nach vorheriger Chemotherapie

Die Ergebnisse der globalen RATIONALE 302 Phase 3-Studie zeigten, dass TEVIMBRA das Überleben von Patienten, die zuvor eine systemische Behandlung erhalten hatten, im Vergleich zu einer...

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Results from the global, Phase 3 RATIONALE 302 trial showed TEVIMBRA prolonged the survival of patients who received prior systemic treatment compared to chemotherapy Approval represents the...

マックス財団、ベイジーン、ベイジーン財団の協力により、低・中所得国の慢性リンパ性白血病患者にBRUKINSA®を初回投与

低・中所得29か国のうち、アルメニアとネパールより投与を開始 (ビジネスワイヤ) -- 世界中の患者に医薬品、テクノロジー、支援サービスを提供することにより、健康の公平性促進に取り組む世界的な非営利組...

The Max Foundation、BeiGene和BeiGene Foundation共同向中低收入國家的慢性淋巴性白血病病患提供首批BRUKINSA®藥物

亞美尼亞和尼泊爾是29個接受BRUKINSA的國家中的首批國家 (美國商業資訊)-- 致力於透過向全球病患提供藥物、科技和支援性服務來加速實現健康公平的全球性非營利組織The Max Foundation (Max)、全球性腫瘤公司Bei...

Les premières doses de BRUKINSA® sont administrées à des patients atteints de leucémie lymphoïde chronique dans des pays à revenus faibles et moyens, grâce à la collaboration de la Max Foundation, de BeiGene et de la BeiGene Foundation

L’Arménie et le Népal sont les premiers des 29 pays à recevoir BRUKINSA La Max Foundation (Max), une organisation mondiale à but non lucratif dont l’objectif est d’accélérer l’équité en matière...

Erste Dosen von BRUKINSA ® für Patienten mit chronischer lymphatischer Leukämie in Ländern mit niedrigem und mittlerem Einkommen im Rahmen der Zusammenarbeit von The Max Foundation, BeiGene und der BeiGene Foundation

Armenien und Nepal sind die ersten von 29 Ländern, die BRUKINSA erhalten Die Max Foundation (Max), eine weltweit tätige gemeinnützige Organisation, die sich für mehr Chancengleichheit im...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

BGNE Discussion

View Posts
MiamiGent MiamiGent 9 months ago
BGNE having a nice bounce and a good, steady day
9:40 AM +5.31%
10:45 AM +5.51%
3:18 PM +6.46%
https://stockcharts.com/h-sc/ui?s=BGNE
👍️0
MiamiGent MiamiGent 1 year ago
BGNE $271.915 +$6.91 (+2.609%)
Bid x Size
$271.06 x 1 Ask x Size $272.91 x 3
Volume 48,899

https://stockcharts.com/h-sc/ui?s=BGNE

BeiGene Says Brukinsa Gets UK Marketing Authorization for Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma
MT NEWSWIRES

08:38 AM EST, 01/19/2023 (MT Newswires) -- BeiGene (BGNE) said Thursday that the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorizations for Brukinsa for the treatment of both chronic lymphocytic leukemia and marginal zone lymphoma.
(con't)
👍️0
MiamiGent MiamiGent 1 year ago
BGNE presently $269.42 +$6.19 (+2.35%)

Little drop from its ascent

Just took a position

https://stockcharts.com/h-sc/ui?s=BGNE
👍️0
luke424 luke424 2 years ago
Looking good!
👍️0
luke424 luke424 2 years ago
Last year, I think Bernstein had price target of $431. If SEC and China reach full agreement, the possibility is there. IP
👍️0
luke424 luke424 2 years ago
Great, Old timers will soon begin loading up China stocks!
https://www.bloomberg.com/news/articles/2022-04-01/china-weighs-giving-u-s-full-access-to-audits-of-most-firms?srnd=markets-vp
👍️0
luke424 luke424 2 years ago
Made a nice bet. Bought yesterday. https://www.cnbc.com/2022/04/01/china-securities-regulator-on-us-listed-chinese-stocks-audit-delisting.html
👍️0
north40000 north40000 4 years ago
AMGN to acquire 20% stake in BGNE; joint development of oncology assets in China.
👍️0
StockLearner2011 StockLearner2011 5 years ago
Market sentiment is not good for pharmaceutical company, but BGNE is still a bargain. Just bought 1000 shares waiting for rebound
👍️0
StockLearner2011 StockLearner2011 5 years ago
Hope no one will jump down the window if buyout happens ??
👍️0
StockLearner2011 StockLearner2011 5 years ago
Buy out is not going to happen that soon, but the stock price will make a big strike towards $200 soon enough
👍️0
StockLearner2011 StockLearner2011 5 years ago
Looking at insider transactions, the total shares bought by insiders over the course of 12 months is a lot more than they sold. The stock has great upward movement potential
👍️0
StockLearner2011 StockLearner2011 6 years ago
Howard Liang could have made 40000 X $22 = $880000 more if he held the shares for 2 more days to sell them
https://www.gurufocus.com/news/648598/beigene-ltd-bgne-ceo-john-oyler-sold-144-million-of-shares
👍️0
StockLearner2011 StockLearner2011 6 years ago
https://www.gurufocus.com/news/648598/beigene-ltd-bgne-ceo-john-oyler-sold-144-million-of-shares
👍️0
StockLearner2011 StockLearner2011 6 years ago
https://www.gurufocus.com/news/648598/beigene-ltd-bgne-ceo-john-oyler-sold-144-million-of-shares
👍️0
StockLearner2011 StockLearner2011 6 years ago
https://stocknewstimes.com/2018/03/21/beigene-ltd-bgne-cfo-howard-liang-sells-10872-shares.html
👍️0
StockLearner2011 StockLearner2011 6 years ago
https://finviz.com/quote.ashx?t=Bgne
The chart looks traight shooting up!
👍️0
StockLearner2011 StockLearner2011 6 years ago
Strong buy!
👍️0
StockLearner2011 StockLearner2011 6 years ago
Hot stock. It's looking strong!
👍️0
SweepsMcGee SweepsMcGee 6 years ago
BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China

BEIJING, China, and CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that REVLIMID® (lenalidomide) has been approved by the China Food and Drug Administration (CFDA) for the treatment of multiple myeloma (MM) in combination with dexamethasone in adult patients with previously untreated MM who are not eligible for transplant. REVLIMID is an oral immunomodulatory drug that was first approved by the CFDA in China in 2013 for the treatment of MM in combination with dexamethasone, in adult patients who have received at least one prior therapy. It is currently marketed in China by BeiGene under an exclusive license from Celgene Corporation.

“REVLIMID is an important part of our commercial and development plans in China, where we are expanding our portfolio and commercial footprint. In China, where the incidence of multiple myeloma is on the rise due to an aging population and improved diagnosis, we are hopeful that newly diagnosed patients will have a meaningful long-term benefit from this approval,” commented John V. Oyler, Founder, Chief Executive Officer, and Chairman of BeiGene.

In a large randomized, three-arm, open-label Phase 3 trial (CC-5013-MM-020) conducted to compare the efficacy and safety of REVLIMID and low dose dexamethasone (Rd) to that of melphalan, prednisone and thalidomide (MPT) in patients with newly diagnosed multiple myeloma (NDMM) who were not eligible for transplant, continuous REVLIMID plus dexamethasone (Rd continuous) significantly improved median progression-free survival (PFS) compared to the MPT arm with a hazard ratio (HR) of 0.72 (95% Confidence Interval (CI): 0.61-0.85, p <0.0001) and a median PFS of 25.5 vs. 21.2 months. The median overall survival was 10.4 months longer with Rd continuous vs. MPT (58.9 vs. 48.5 months, HR of 0.75 (95% CI: 0.62-0.90)). Similarly, the response rate was also higher with Rd continuous compared with MPT (75.1% vs. 62.3%); with a complete response in 15.1% of Rd continuous arm patients vs. 9.3% in the MPT arm.

The most common grade 3/4 adverse events (occurring in ≥ 10% of patients in any subgroup) in the Rd continuous arm, Rd for 72 weeks (18 cycles; Rd18 arm) or MPT arm in the trial included neutropenia (28%, 27%, 45%, respectively), anemia (18%, 16%, 19%), thrombocytopenia (8%, 8%,11%) and pneumonia (11%, 11%, 8%).

About Multiple Myeloma

Multiple myeloma is an incurable and life-threatening blood cancer that is characterized by tumor proliferation and suppression of the immune system.i It can appear as both a tumor and/or an area of bone loss, and it affects the places where bone marrow is active in an adult: the hollow area within the bones of the spine, skull, pelvis, rib cage, and the areas around the shoulders and hips.ii MM is the second most commonly diagnosed blood cancer. According to the International Myeloma Foundation, there are an estimated 750,000 MM patients worldwide.iii

About REVLIMID

In China, REVLIMID is now approved in combination with dexamethasone for the treatment of adult NDMM patients who are not eligible for transplant. It received approval in China in 2013 for the treatment of MM in combination with dexamethasone, in adult patients who have received at least one prior therapy.

REVLIMID, in combination with dexamethasone, is approved in the United States, in Europe, in Japan and in around 25 other countries for the treatment of adult patients with previously untreated MM who are not eligible for transplant. REVLIMID is also approved in combination with dexamethasone for the treatment of MM patients who have received at least one prior therapy in nearly 70 countries, encompassing Europe, the Americas, the Middle East and Asia, and in combination with dexamethasone for the treatment of patients whose disease has progressed after one therapy in Australia and New Zealand.

REVLIMID is also approved in the United States, Canada, Switzerland, Australia, New Zealand and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities and in Europe for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

In addition, REVLIMID is approved in the United States and Europe for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. In Switzerland, REVLIMID is indicated for the treatment of patients with relapsed or refractory MCL after prior therapy that included bortezomib and chemotherapy/rituximab.

REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
👍️0
north40000 north40000 6 years ago
BGNE: New message board for a Chinese biotech company. CEO has Ph. D. from Texas-based UTSW. The company has recently raised substantial funds, and is focused on immuno-therapy market. Its share price has risen faster in past 6 months than others on my watch list.
👍️0

Your Recent History

Delayed Upgrade Clock